-
Mashup Score: 3ASCO GU 2022: PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness - 2 year(s) ago
ASCO GU 2022 PROMISE Registry, prostate cancer patients with germline mutations in genes involved in DNA damage repair, treatment guidelines recommend genetic testing in high-risk localized, node-positive, and metastatic prostate cancer, real-world understanding of the prevalence of potentially targetable DNA damage repair alterations the PROMISE registry prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 7Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients - 2 year(s) ago
AbstractBackground. Although use of gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is an established strategy to protect ovarian function in
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
To mark the end of 2021, honored and proud to share updated results of #PROMISE #GIM6 trial confirming long-term safety of #GnRHa during #chemotherapy to preserve ovarian function in premenopausal #BreastCancer patients @JNCI_Now @OncoAlert #ASCO21 #bcsm https://t.co/4awHrcXVw4 https://t.co/35WJOCqJQV
-
-
Mashup Score: 0Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors - 2 year(s) ago
Background Epithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. A multifactorial risk model based on known genetic and epidemiological risk factors (RFs) for EOC can help identify women at higher risk who could benefit from targeted screening and prevention. Methods We developed a multifactorial…
Source: Journal of Medical GeneticsCategories: Latest Headlines, Oncologists2Tweet-
Delighted to be part of the team and see our paper on OC risk prediction out in JMG. Congrats prof Antoniou @paulpharoah @Prof_UMenon @eveappeal #ukctocs team #promise team https://t.co/wSwgNuLwXj
-
-
Mashup Score: 4Meeting Library | Meeting Library - 3 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to #ASCO21: important data by the Italian #BreastCancer group #GIM with the final analysis of #PROMISE-#GIM6 trial on #GnRHa use during #chemotherapy for ovarian function preservation @OncoAlert #UNIGEnonsiferma #bcsm Full abstract here: https://t.co/rEGoQTcrgn https://t.co/5kT9YQH5Wb
-
-
Mashup Score: 0
AbstractSTUDY QUESTION. Does goserelin, a GnRH agonist, have a protective effect in young breast cancer patients in terms of ovarian reserve markers anti-Müller
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Finally a large study showing the protective effect of #GnRHa use during #chemotherapy on ovarian reserve (#AMH & #AFC) in young #BreastCancer patients: stay tuned for the upcoming final analysis of the #PROMISE-#GIM6 trial @OncoAlert #SurvOnc #fertility https://t.co/A3xQB8sgK5
-
-
Mashup Score: 0
CAD-RADS was developed to standardize communication of per-patient maximal stenosis on coronary CT angiography (CCTA) and provide treatment recommendations and may impact primary prevention care and resource utilization. The authors sought to evaluate CAD-RADS adoption on preventive medical therapy and risk factor control amongst a mixed provider population.
Categories: Cardiologists, Latest HeadlinesTweet-
@purviparwani Yes- papers from #PROMISE trial and in UK #SCOTHEART. @drdthomas30 just published real world experience and management impact in JCCT... https://t.co/CCBu0GKsWw @ghoshhajra has important data from ER experience at MGH
-
-
Mashup Score: 2Global Risk Assessment and Coronary Artery Calcium Scoring in Low-Intermediate Risk Women | Circulation: Cardiovascular Imaging - 4 year(s) ago
Accurate atherosclerotic cardiovascular (ASCVD) risk assessment is needed for both women and men to identify and intervene in individuals at risk for ASCVD. Previously developed global risk scores, such as the Framingham Risk Score, have had many limitations, particularly in women who are routinely categorized as lower risk than men.1,2 The newer ASCVD Risk Score3 that makes up the current…
Source: www.ahajournals.orgCategories: CardiologistsTweet-
Positive predictive value of atomic stress test vs stress test seen by #PROMISE Study was greater in 💃🏻 #YeSCCT @Heart_SCCT @AChoiHeart @RonBlankstein @lesleejshaw @hvanspall ♥️CAC score helps reclassify patients https://t.co/khSEq9oYEx https://t.co/pVFbeqKs3N
-
#PROMISE Registry: A #ProstateCancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Presentation by @Cpaller @HopkinsMedicine. #GU22 written coverage by @aloktewar @DanaFarber on UroToday > https://t.co/H8avn56cJ5 @ASCO https://t.co/5Dqycaoyt5